Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with cancer, according to a press release from the American Society for Radiation Oncology (ASTRO).1 In Read more…
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent use after surgery, according to the company responsible for the PD-1 inhibitor, Merck.1 This decision Read more…
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Doll, M.D., from the University of Washington in Seattle, and colleagues compared the performance of Read more…
For children with high-risk group 3 medulloblastoma, therapy intensification with carboplatin improves event-free survival, according to a study published online July 22 in JAMA Oncology. Sarah E. S. Leary, M.D., from Seattle Children’s, and colleagues examined therapy intensification with carboplatin as a radiosensitizer and isotretinoin as a proapoptotic agent in children Read more…
For adolescents and young adults (AYAs) with cancer, living in rural counties and living farther from the reporting hospital are associated with later-stage diagnoses and increased mortality, according to a study published online July 8 in Cancer. Kimberly J. Johnson, M.P.H., Ph.D., from Washington University in St. Louis, and colleagues obtained Read more…